The AAO in Orlando is seen as a worldwide barometer for innovations in ophthalmology. Franz Aigner, Medical Technology Head of Sales at WILD, was there to assess the latest developments.

What impressions do you bring back from the US?
Franz Aigner: “Opthalmology is more dynamic than ever. We are particularly proud of having been directly involved in the creation of various products and assemblies on display there. WILD enjoys a reputation of being an expert among key players. Be it in retina tomographs (OCT), digital phoropters, or accurately positionable stands, our experience from successfully implemented product series gives us a technological edge that benefits customers in the form of faster market maturity and cost efficiency.”

Which trends are dominating the industry?
“The biggest game changer is AI. When it comes to imaging, e.g. in the case of OCTs or fundus photography, AI can sometimes analyse retina images more precisely than experts. Robotics will also have a massive impact on surgical precision in the future, though much of that is still in a development stage. In addition, western providers are increasingly focusing on high-end quality to set themselves apart from their Asian competitors, e.g. through extremely high resolutions and faster image acquisition.”

Which point-of-care developments were evident at the fair?
“Handheld and wearable devices for initial analysis at the optician or in primary care centres must become more robust without losing precision. Since WILD covers optics, mechanics and electronics technologies, we are the ideal partner for these compact all-in-one solutions. Moreover, optics must always be calibrated before delivery. Should those fine adjustments suffer during transport, manufacturers will need expensive specialists on site to recalibrate those devices. We develop products that are so stable, however, that they can survive transport unscathed and can be immediately put into operation without significant effort.”

Since 2025, new import tariffs are weighing on the US market. How are customers reacting to that?
”Due to the tariffs, but also due to bureaucracy and high energy costs in Europe, many European customers are thinking of establishing production sites in the US, at least for individual components. For them, our FDA certification is a key argument.  Those who want to be successful in this important market need partners who can deal with the regulatory requirements. In addition, we are currently increasing our support for our customers through value analysis projects to help them save additional costs in other areas.“